Function Oncology

Function Oncology is a biotechnology company that leverages a CRISPR-enabled platform to understand cancer biology and develop the next generation of targeted cancer therapies. The company uses CRISPR gene editing technology to conduct functional genomic screens that identify cancer dependencies and therapeutic targets, enabling the discovery of novel drug candidates that address specific genetic vulnerabilities in tumor cells. By systematically mapping which genes are essential for cancer cell survival across different tumor types, Function Oncology aims to develop precision oncology treatments that are more effective and less toxic than conventional chemotherapy. The platform integrates high-throughput CRISPR screening with computational biology to prioritize targets and accelerate drug development. Founded in 2018 and headquartered in San Diego, California, the company has raised $28 million in Series A funding from investors including Andreessen Horowitz, Casdin Capital, Alexandria, S32, and Section 32.